Eosinophils as a non-invasive marker to assess inflammatory activities in those suffering from chronic obstructive pulmonary disease
https://doi.org/10.21292/2075-1230-2018-96-10-54-61
Abstract
The article presents the review of latest studies devoted to assessment of the eosinophilic inflammation in chronic obstructive pulmonary disease (COPD) and opportunities for differential therapy of stable COPD and COPD therapy during exacerbation. Currently, there is no final definition what threshold blood level of eosinophils can be used for decision making in clinical practice. The only thing found out was that the high blood level of eosinophils could be a predictor of the risk of frequent exacerbations and the effectiveness of treatment with glucocorticosteroids.
About the Authors
M. A. Kаrnаushkinа
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Maria A. Karnaushkina - Doctor of Medical Sciences, Professor of Hospital Therapy Department no. 2.
8, Bd. 2, Trubetskaya St., Moscow, 119991.
R. S. Dаnilov
Medical Rehabilitation Center of the Ministry of Economic Development of Russia
Russian Federation
Russian Federation
Ruslan S. Danilov - Pulmonologist of Therapy Department.
43, Lomonosovsky Ave., Moscow, 119192.
References
1. Aaron S.D., Vandemheen K.L., Maltais F. et al. TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax, 2013, vol. 68, pp. 142-148. doi: 10.1136/thoraxjnl-2012-202432.
2. Agustı A., Celli B. Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterization. Eur. Respir. J., 2011, vol. 38, pp. 749-751. doi: 10.1183/09031936.00062211.
3. Angelis N., Porpodis K., Zarogoulidis P. et al. Airway inflammation in chronic obstructive pulmonary disease. J. Thorac. Dis., 2014, vol. 6, suppl. 1, pp. S167-S172.
4. Bafadhel M., Davies L., Calverley P.M. et al. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur. Respir. J., 2014, vol. 44, no. 3, pp. 789-791. doi: 10.1183/09031936.00062614.
5. Bafadhel M., McKenna S., Terry S. et al. Acute exacerbations of COPD: identification of biological clusters and their biomarkers. Am. J. Respir. Crit. Care Med., 2011, vol. 184, pp. 662-671. doi: 10.1164/rccm.201104-0597OC.
6. Bafadhel M., McKenna S., Terry S. et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am. J. Respir. Crit. Care Med., 2012, vol. 186, pp. 48-55. doi: 10.1164/rccm.201108-1553OC.
7. Barnes P.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol., 2016, vol. 138, no. 1, pp. 16-27.
8. Chou K.T., Su K.C., Huang S.F. et al. Exhaled nitric oxide predicts eosinophilic airway inflammation in COPD. Lung, 2014, vol. 192, no. 4, pp. 499-504. doi: 10.1007/s00408-014-9591-9598.
9. Dransfield M.T., Bourbeau J., Jones P.W. et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir. Med., 2013, vol. 1, pp. 210-223. doi: 10.1016/S2213-2600(13)70040-7.
10. Durham A.L., Caramori G., Chung K.F., Adcock I.M. Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Transl. Res., 2016, vol. 167, no. 1, pp. 192-203. doi: 10.1177/2040622315609251.
11. Dweik R.A., Boggs P.B., Erzurum S.C. et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am. J. Respir. Crit. Care Med., 2011, vol. 184, no. 5, pp. 602-615. doi: 10.1164/rccm.9120-11ST.
12. Eltboli O., Mistry V., Barker B., Brightling C. E. Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology, 2015, vol. 20, no. 4, pp. 667-670. doi: 10.1111/resp.12475.
13. Gao J., Zhang M., Zhou L. et al. Correlation between fractional exhaled nitric oxide and sputum eosinophilia in exacerbations of COPD. Int. J. Chron. Obstruct. Pulmon. Dis., 2017, vol. 12, pp. 1287-1293, doi: 10.2147/COPD.S134998.
14. George L., Brightling C.E. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther. Adv. Chronic. Dis., 2016, vol. 7, no. 1, pp. 34-51. doi: 10.1016/j.jaci.2016.05.011.
15. George L., Brightling C.E. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther. Adv. Chronic. Dis., 2016, vol. 7, no. 1, pp. 34-51. doi: 10.1177/2040622315609251.
16. Hambleton K., Pavord I.D. What can we learn from blood granulocyte patterns in patients with asthma? Eur. Respir. J., 2016, vol. 48, no. 4, pp. 976-978. doi: 10.1183/13993003.01567-2016.
17. Hastie A.T., Martinez F.J., Curtis J.L. et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir. Med., 2017, vol. 5, no. 12, pp. 956-967. doi: 10.1016/S2213-2600(17)30432-0.
18. Huang A.X., Lu L.W., Liu W.J., Huang M. Plasma inflammatory cytokine IL-4, IL-8, IL-10, and TNF-α levels correlate with pulmonary function in patients with asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome. Med. Sci. Monit., 2016, vol. 9, no. 22, pp. 2800-2808.
19. Katz L.E., Gleich G.J., Hartley B.F. et al. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann. Am. Thorac. Soc., 2014, vol. 11, pp. 531-536. doi: 10.1513/AnnalsATS.201310-354OC.
20. Kolsum U., Damera G., Pham T.H. et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J. Allergy Clin. Immunol., 2017, vol. 140, no. 4, pp. 1181-1184.e7. doi: 10.1016/j.jaci.2017.04.027.
21. Magnussen H., Disse B., Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med., 2014, vol. 37, pp. 1285-1294. doi: 10.1056/NEJMoa1407154.
22. Magnussen H., Watz H., Kirsten A. et al. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale. Respir. Med., 2014, vol. 108, pp. 593-599. doi: 10.1016/j.rmed.2014.01.002.
23. Malerba M., Radaeli A., Olivini A. et al. Exhaled nitric oxide as a biomarker in COPD and related comorbidities. Biomed. Res. Int., 2014, 271918. doi: 10.1155/2014/271918.
24. Meyer K.C., Raghu G., Baughman R.P. et al. American Thoracic Society Committee on BAL in Interstitial Lung Disease. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am. J. Respir. Crit. Care Med., 2012, vol. 185, no. 9, doi: 10.1164/rccm.201202-0320ST.
25. Meyer K.C., Raghu G., Baughman R.P. et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. American Thoracic Society Committee on BAL in Interstitial Lung Disease. Am. J. Respir. Crit. Care Med., 2012, vol. 185, no. 9, pp. 1004-1014. doi: 10.1164/rccm.201202-0320ST.
26. Papaioannou A.I., Kostikas K., Papaporfyriou A. et al. Emphysematous Phenotype is Characterized by Low Blood Eosinophils: A Cross-Sectional Study. J. COPD, 2017, vol. 14, no. 6, pp. 635-640. doi: 10.1080/15412555.2017.1386644.
27. Pascoe S., Locantore N., Dransfield M., Barnes N.C., Pavord I.D. Blood eosiophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parrallel randomised controlled trials. Lancet Respir. Med., 2015, vol. 3, no. 6, pp. 435-442. doi: 10.1016/S2213-2600(15)00106-X.
28. Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax, 2016, vol. 71, no. 2, pp. 118-125. doi: 10.1136/thoraxjnl-2015-207021.
29. Rosenberg H.F., Dyer K.D., Foster P.S. Eosinophils: changing perspectives in health and disease. Nat. Rev. Immunol., 2013, vol. 13, no. 1, pp. 9-22. doi: 10.1038/nri3341.
30. Saetta M., Di Stefano A., Maestrelli P. et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am. J. Respir. Crit. Care Med., 1994, vol. 150, 6 Pt. 1, pp. 1646-1652. doi: 10.1164/ajrccm.150.6.7952628.
31. Schleich F., Corhay J.L., Louis R. Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD. Eur. Respir., 2016, vol. 47, pp. 1562-1564. doi: 10.1183/13993003.01659-2015.
32. Siddiqui S.H., Guasconi A., Vestbo J. et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2015, vol. 192, no. 4, pp. 523-525. doi: 10.1164/rccm.201502-0235LE.
33. Singh D., Kampschulte J., Wedzicha J.A. et al. A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. Eur. Respir. J., 2013, vol. 41, no. 1, pp. 12-17. doi: 10.1186/s40413-016-0123-2.
34. Singh D., Kolsum U., Brightling C.E. et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur. Respir. J., 2014, vol. 44, no. 6, pp. 1697-700. doi: 10.1183/09031936.00162414.
35. Siva R., Green R.H., Brightling C.E. et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur. Respir. J., 2007, vol. 29, pp. 906-913. doi: 10.1183/09031936.00146306.
36. Soter S., Barta I., Antus B. Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide. Inflammation, 2013, vol. 36, no. 5, pp. 1178-1185, doi: 10.1007/s10753-013-9653-8.
37. Tworek D., Antczak A. Eosinophilic COPD ‒ a distinct phenotype of the disease. Adv. Respir. Med., 2017, vol. 85, pp. 271-276. doi: 10.5603/ARM.2017.0045.
38. Varricchi G., Bagnasco D., Borriello F., Heffler E., Canonica G.W. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr. Opin. Allergy Clin. Immunol., 2016, vol. 16, no. 2, pp. 186-200. doi: 10.1097/ACI.0000000000000251.
39. Vedel-Krogh S., Nielsen S.F., Lange P., Vestbo J., Nordestgaard B.G. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The copenhagen general population study. Am. J. Respir. Crit. Care Med., 2016, vol. 193, no. 9, pp. 965-974. doi: 10.1164/rccm.201509-1869OC.
40. Vogelmeier C.F., Criner G.J., Martinez F.J. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report. GOLD Executive Summary. Am. J. Respir. Crit. Care Med., 2017, vol. 195, no. 5, pp. 557-582. doi: 10.1164/rccm.201701-0218PP.
41. Watz H., Tetzlaff K., Wouters E.F. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir. Med., 2016, vol. 4, no. 5, pp. 390-398. doi: 10.1016/S2213-2600(16)00100-4.
42. Wedzicha J.A., Ers Co-Chair, Miravitlles M., Hurst J.R. et al. Management of COPD exacerbations: a European Respiratory Society. American Thoracic Society guideline. Eur. Respir. J., 2017, vol. 49, no. 3, doi: 10.1183/13993003.00791-2016.
43. Zsoka Weiszhar, Ildiko Horvath. Induced sputum analysis: step by step. Breathe, 2013, vol. 9, pp. 300-306. doi: 10.1183/20734735.042912.
Review
For citations:
Kаrnаushkinа M.A., Dаnilov R.S. Eosinophils as a non-invasive marker to assess inflammatory activities in those suffering from chronic obstructive pulmonary disease. Tuberculosis and Lung Diseases. 2018;96(10):54-61. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-10-54-61
Views:
1410
Email this article 